Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with MS: drug showdown begins

NCT ID NCT04926818

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two newer multiple sclerosis drugs, ofatumumab and siponimod, against an older one, fingolimod, in 129 children aged 10 to 17. The goal is to see if the newer drugs are at least as good at preventing MS relapses. Participants take one of the three drugs for two years, and researchers track how many relapses occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ofatumumab, Siponimod, and Fingolimod (drugs to control MS relapses)

What this could lead to

If successful, this could show that newer drugs like ofatumumab or siponimod work as well as or better than fingolimod for children with MS, offering more options to control relapses.

What could go wrong

This is a non-inferiority trial, meaning it aims to show the new drugs are not worse than the standard, not necessarily better. Results may not apply to all MS types, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS (MS)

Contacts and locations

Locations

  • Arkansas Childrens Hosp Rsch Inst

    Little Rock, Arkansas, 72202, United States

  • Axiom Clinical Research of Florida

    Tampa, Florida, 33609, United States

  • Childrens Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104 4399, United States

  • Childrens National Medical Center

    Washington D.C., District of Columbia, 20010, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Parkville, Victoria, 3052, Australia

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Esneux, 4130, Belgium

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Curitiba, Paraná, 81210-310, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90430-001, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 05403-000, Brazil

  • Novartis Investigative Site

    Montreal, Quebec, H3A 2B4, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H3T 1C5, Canada

  • Novartis Investigative Site

    Lo Barnechea, Santiago Metropolitan, 7691236, Chile

  • Novartis Investigative Site

    Zagreb, 10000, Croatia

  • Novartis Investigative Site

    Tallinn, 11315, Estonia

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, 94275, France

  • Novartis Investigative Site

    Montpellier, 34090, France

  • Novartis Investigative Site

    Strasbourg, 67000, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, 37075, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Guatemala City, 01015, Guatemala

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110017, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700017, India

  • Novartis Investigative Site

    Petah Tikva, 4920235, Israel

  • Novartis Investigative Site

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    Naples, 80131, Italy

  • Novartis Investigative Site

    Riga, LV-1004, Latvia

  • Novartis Investigative Site

    Mexico City, Mexico City, 06700, Mexico

  • Novartis Investigative Site

    Mexico City, Mexico City, 06720, Mexico

  • Novartis Investigative Site

    Gdansk, 80-214, Poland

  • Novartis Investigative Site

    Lodz, 93-338, Poland

  • Novartis Investigative Site

    Poznan, 60-355, Poland

  • Novartis Investigative Site

    Warsaw, 04-730, Poland

  • Novartis Investigative Site

    Coimbra, 3000-602, Portugal

  • Novartis Investigative Site

    Lisbon, 1169-050, Portugal

  • Novartis Investigative Site

    Belgrade, 11000, Serbia

  • Novartis Investigative Site

    Bratislava, 833 40, Slovakia

  • Novartis Investigative Site

    Barakaldo, Vizcaya, 48903, Spain

  • Novartis Investigative Site

    Seville, 41009, Spain

  • Novartis Investigative Site

    Tainan, 704302, Taiwan

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

  • Novartis Investigative Site

    Samsun, Atakum, 55200, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Fatih, 34098, Turkey (Türkiye)

  • Novartis Investigative Site

    Izmir, Karsiyaka, 35575, Turkey (Türkiye)

  • Novartis Investigative Site

    Kocaeli, 41380, Turkey (Türkiye)